The recent literature regarding prostate cancer has demonstrated that SPDEF CpG island methylation can be reliably detected in peripheral blood through PCR-based assays [41], enabling a non-invasive and tumor-specific approach to supplement diagnostic and therapeutic management. This evidence concerns the gene SPDEF and prostate cancer.